Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AGEN2373

Monoclonal antibody · Agonist of CD137 (TNFRSF9) · developed by Agenus

Phase 1/2 Most advanced trial

AGEN Developer

1 Registered trials

What is AGEN2373?

AGEN2373 is a fully human IgG1 agonistic monoclonal antibody targeting CD137 (4-1BB), a costimulatory receptor on T cells and NK cells. It activates CD137 signaling in a conditionally-active manner, enhancing cytotoxic T-lymphocyte proliferation and NK-mediated tumor killing while suppressing T-regulatory cells. The drug is being studied in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: CD137 (TNFRSF9)
Mechanism: Agonist of CD137 (TNFRSF9)
Pathways: T-cell proliferation and survival, NK cell activation, cytotoxic T-lymphocyte response, Treg suppression
Therapy area: Oncology
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06782932	Phase 1/2	Pancreatic Cancer	Recruiting	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer

Other drugs acting on TNFRSF9

Acasunlimab Phase 3 ADG106 Phase 1/2 ADG206 Phase 1 ALG.APV-527 Phase 1/2 CTX-471 Phase 1/2 Enristomig Phase 1

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 Balstilimab Phase 2/3 BMS-986442 Phase 1 Botensilimab Phase 2/3 QS21 Phase 2 Vitespen Phase 2 Zalifrelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind AGEN2373

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z